Screen Shot 2017-09-18 at 6.06.24 PM.png

peter h. Seeberger

Prof. Seeberger studied chemistry in Erlangen (Germany) and completed a PhD in biochemistry in Boulder (USA). After performing research at the Sloan-Kettering Cancer Center in New York he became Firmenich Associate Professor of Chemistry with tenure at MIT. After six years as Professor at ETH Zurich he assumed positions as Director at the Max-Planck Institute for Colloids and Interfaces in Potsdam and Professor at the Freie University of Berlin in 2009. His research has been documented in over 450 peer-reviewed journal articles, four books, more than 40 patent families, and more than 800 invited lectures. 

In 2013 he was elected to the Berlin-Brandenburg Academy of Sciences. The research in his laboratory has given rise to eight successful companies in the USA, Switzerland and Germany. 

Prof. Seeberger pioneered automated carbohydrate assembly, a technology (commercialized by GlycoUniverse (Berlin) that provides rapid access to glycans used as vaccines (Vaxxilon AG, Basel) and diagnostics (BDW Berlin Diagnostic Works, Berlin). His work in ow chemistry has given rise to ArtemiFlow (2012) and FluxPharm (2015) that focus on the production of affordable medications. 

 

Screen Shot 2017-09-18 at 6.06.48 PM.png

Kerry gilmore

Dr. Kerry Gilmore was born in Brewster, Massachusetts, USA in 1984. After receiving bachelor degrees in biology and chemistry from Roger Williams University, he moved on to his Ph.D. in organic chemistry at Florida State University from Prof. Igor V. Alabugin examining the Baldwin rules and the cyclizations of alkynes, during which time he also spent a year in Bologna, Italy as a Fulbright Scholar with Prof. Chryssostomos Chatgilialoglu. 

Kerry then moved to the Max-Planck Institute in Berlin for postdoctoral work under Prof. Peter H. Seeberger, where he was promoted to Group Leader in 2014. His current research interests include the development of continuous and modular reaction modules, creating chemical assembly systems for the synthesis of customizable small molecules as well as for the inexpensive production of active pharmaceutical ingredients (medicines) such as antimalarials and generic drugs. In 2015 he co-founded FluxPharm (Potsdam) that develops production methods for affordable drugs.